These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18486283)

  • 1. Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.
    Florese RH; Wiseman RW; Venzon D; Karl JA; Demberg T; Larsen K; Flanary L; Kalyanaraman VS; Pal R; Titti F; Patterson LJ; Heath MJ; O'Connor DH; Cafaro A; Ensoli B; Robert-Guroff M
    Vaccine; 2008 Jun; 26(26):3312-21. PubMed ID: 18486283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.
    Cafaro A; Bellino S; Titti F; Maggiorella MT; Sernicola L; Wiseman RW; Venzon D; Karl JA; O'Connor D; Monini P; Robert-Guroff M; Ensoli B
    J Virol; 2010 Sep; 84(17):8953-8. PubMed ID: 20554774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
    Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M
    J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of MHC class I and II haplotypes on the experimental infection of Mauritian cynomolgus macaques with SHIVSF162P4cy.
    Borsetti A; Maggiorella MT; Sernicola L; Bellino S; Ferrantelli F; Belli R; Fulgenzi D; Mee ET; Rose NJ; Cafaro A; Ensoli B; Titti F
    Tissue Antigens; 2012 Jul; 80(1):36-45. PubMed ID: 22494179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.
    Florese RH; Demberg T; Xiao P; Kuller L; Larsen K; Summers LE; Venzon D; Cafaro A; Ensoli B; Robert-Guroff M
    J Immunol; 2009 Mar; 182(6):3718-27. PubMed ID: 19265150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.
    Cafaro A; Caputo A; Maggiorella MT; Baroncelli S; Fracasso C; Pace M; Borsetti A; Sernicola L; Negri DR; Ten Haaft P; Betti M; Michelini Z; Macchia I; Fanales-Belasio E; Belli R; Corrias F; Buttò S; Verani P; Titti F; Ensoli B
    J Med Primatol; 2000 Aug; 29(3-4):193-208. PubMed ID: 11085582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
    Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
    DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein.
    Silvera P; Richardson MW; Greenhouse J; Yalley-Ogunro J; Shaw N; Mirchandani J; Khalili K; Zagury JF; Lewis MG; Rappaport J
    J Virol; 2002 Apr; 76(8):3800-9. PubMed ID: 11907220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses.
    Reimann KA; Parker RA; Seaman MS; Beaudry K; Beddall M; Peterson L; Williams KC; Veazey RS; Montefiori DC; Mascola JR; Nabel GJ; Letvin NL
    J Virol; 2005 Jul; 79(14):8878-85. PubMed ID: 15994781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mhc haplotype M3 is associated with early control of SHIVsbg infection in Mauritian cynomolgus macaques.
    Mee ET; Berry N; Ham C; Aubertin A; Lines J; Hall J; Stebbings R; Page M; Almond N; Rose NJ
    Tissue Antigens; 2010 Sep; 76(3):223-9. PubMed ID: 20403147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).
    Borsetti A; Baroncelli S; Maggiorella MT; Moretti S; Fanales-Belasio E; Sernicola L; Tripiciano A; Macchia I; Michelini Z; Belli R; Farcomeni S; Pavone-Cossut MR; Negri D; Caputo A; Bellino S; Butto S; Titti F; Cafaro A; Ensoli B
    Viral Immunol; 2009 Apr; 22(2):117-24. PubMed ID: 19326998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of 47 MHC class I sequences in Filipino cynomolgus macaques.
    Campbell KJ; Detmer AM; Karl JA; Wiseman RW; Blasky AJ; Hughes AL; Bimber BN; O'Connor SL; O'Connor DH
    Immunogenetics; 2009 Mar; 61(3):177-87. PubMed ID: 19107381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability.
    Ridolfi B; Genovese D; Argentini C; Maggiorella MT; Sernicola L; Buttò S; Titti F; Borsetti A; Ensoli B
    Virus Genes; 2008 Feb; 36(1):105-15. PubMed ID: 18049888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with recombinant macaque major histocompatibility complex class I and II and human immunodeficiency virus gp140 inhibits simian-human immunodeficiency virus infection in macaques.
    Yang GB; Wang Y; Babaahmady K; Schøller J; Rahman D; Bunnik E; Spallek R; Zong CM; Duan JZ; Qin C; Jiang H; Singh M; Vaughan R; Bergmeier LA; Schuitemaker H; Shao Y; Lehner T
    J Gen Virol; 2012 Jul; 93(Pt 7):1506-1518. PubMed ID: 22492918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques.
    Patterson LJ; Beal J; Demberg T; Florese RH; Malkevich N; Venzon D; Aldrich K; Richardson E; Kalyanaraman VS; Kalisz I; Lee EM; Montefiori DC; Robey FA; Robert-Guroff M
    Virology; 2008 May; 374(2):322-37. PubMed ID: 18252262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques.
    Musich T; Thovarai V; Venzon DJ; Mohanram V; Tuero I; Miller-Novak LK; Helmold Hait S; Rahman MA; Hunegnaw R; Huiting E; Yuan W; O'hUigin C; Hoang T; Sui Y; LaBranche C; Montefiori D; Bear J; Rosati M; Bissa M; Berzofsky JA; Pavlakis GN; Felber BK; Franchini G; Robert-Guroff M
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.